Working… Menu

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02808793
Recruitment Status : Completed
First Posted : June 22, 2016
Last Update Posted : March 13, 2019
Information provided by (Responsible Party):
Allakos, Inc.

Brief Summary:
This is a Phase 1 study to investigate the safety and tolerability of AK002 in patients with indolent systemic mastocytosis (ISM).

Condition or disease Intervention/treatment Phase
Indolent Systemic Mastocytosis Drug: AK002 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 25 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1, Single Ascending Dose and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002 in Patients With Indolent Systemic Mastocytosis
Actual Study Start Date : June 2016
Actual Primary Completion Date : December 2018
Actual Study Completion Date : December 2018

Arm Intervention/treatment
Experimental: AK002
IV dose of AK002
Drug: AK002

Primary Outcome Measures :
  1. To evaluate the safety and tolerability by evaluating Clinical laboratory parameters and adverse events assessed using the CTCAE version 4 [ Time Frame: From study start to Day 85 or early term visit ]

Secondary Outcome Measures :
  1. Evaluate PK of AK002 in patients with ISM [ Time Frame: Through out the study from baseline to Day 85 or early term visit ]
  2. Evaluate the change from baseline in absolute peripheral counts of eosinophils and basophils. [ Time Frame: Through out the study from screening to Day 85 or early term visit ]
  3. Evaluate the change from baseline in serum tryptase and eosinophil grande protein levels. [ Time Frame: Through out the study from screening to Day 29 or early term visit ]
  4. Measure changes form baseline in the 24-hour urine histamine metabolites. [ Time Frame: Starting pre dose on day -1 to days 1, 3 and 4 ]
  5. Mastocytosis Quality of Life Questionnaire [ Time Frame: Through out the study from screening to Day 85 or early term visit ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Provided written informed consent
  2. Male or female aged ≥18 and ≤65 years at the time of signing the informed consent form
  3. Confirmed diagnosis of ISM based on World Health Organization (WHO) criteria (Appendix 1)
  4. Presence of at least 1 of the following SM related symptoms:

    1. Flushing (at least 1 episode per week)
    2. Pruritus (minimum MAS2 score of 4) (Appendix 2)
    3. Diarrhea (minimum MAS2 score of 4) (Appendix 2)
    4. Anaphylaxis (at least 1 episode [grade 2 or higher] within the last 12 months)
  5. Serum total tryptase exceeded 15 ng/mL* at 2 or more measurements obtained 1 or more months apart within the last 2 years (*Note: this varies from the minor criterion of "persistently exceeds 20 ng/mL" in the WHO criteria for diagnosis of ISM)
  6. Willing and able to comply with the study procedures and visit schedule, including follow-up visits
  7. Able to communicate effectively with the study site personnel
  8. Negative Screening urine drug tests (alcohol, amphetamines/methamphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, cotinine, methadone, methaqualone, opiates, phencyclidine)
  9. Negative Screening ova and parasite test
  10. Determined by the Investigator to be in good health as documented by the medical history, physical examination (PE), vital sign assessments, 12- lead ECG, clinical laboratory assessments, and by general observations
  11. Women of child bearing potential, must be using highly effective methods of birth control (failure rate <1% per year when used consistently and correctly) at least 4 weeks prior to Screening until Day 85. Women should be informed of the potential risks associated with becoming pregnant while enrolled. Accepted forms of contraception are implants, injectables, combined oral contraceptives, and some intrauterine devices (IUDs). In addition, a barrier method must always be used concomitantly to the highly effective method. Double-barrier is not considered a highly effective method. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) is not an acceptable means of contraception. Female patients are considered to not be of child-bearing potential when they are post-menopausal for at least 2 years with follicle-stimulating hormone (FSH) levels >40 mIU/mL, are surgically sterilized, or have undergone hysterectomy.
  12. Male patients with female partners of childbearing potential must agree to use a condom without spermicide during sexual activity with female partners of childbearing potential. Female sexual partners of male patients must be willing to avoid pregnancy according to the above described methods.

Exclusion Criteria:

  1. Known hypersensitivity to any constituent of the study drug
  2. Presence of an associated hematologic non-mast-cell lineage disorder or MC leukemia
  3. Any disease or condition (medical or surgical) which, in the opinion of the Investigator, might compromise the hematologic, cardiovascular, pulmonary, renal, gastrointestinal, hepatic, skeletal, or central nervous system; or other conditions that may interfere with the absorption, distribution, metabolism or excretion of AK002, or would place the patient at increased risk
  4. The presence of abnormal laboratory values considered to be clinically significant by the Investigator
  5. Participation in a concurrent interventional study with the last intervention occurring within 30 days prior to administration of study drug (90 days or 5 half-lives, whichever is longer, for biologic products)
  6. Treatment with chemotherapy or radiotherapy in the preceding 6 months
  7. Treatment for a clinically significant helminthic parasitic infection within 6 months of screening
  8. Use during the 7 days before Screening (or 5 half-lives, whichever is longer) or expected to require the use of angiotensin converting enzyme (ACE) inhibitors or beta blockers
  9. Use during the 30 days before Screening (or 5 half lives, whichever is longer) or expected to require the use of omalizumab, immunosuppressive drugs, or systemic corticosteroids with a daily dose >10 mg prednisone or equivalent
  10. Vaccination with live attenuated vaccines within 30 days prior to initiation of treatment in the study, during the treatment period, or vaccination expected within 5 half-lives (4 months) of the study drug administration
  11. Donation or loss of >500 mL of blood within 56 days prior to administration of study drug or donation of plasma within 7 days prior to administration of study drug
  12. Has not refrained from excessive caffeine consumption (>3 cups of coffee per day or equivalent) for 48 hours prior to study drug administration and agreed to this do so throughout the inpatient period
  13. Positive hepatitis serology results, except for vaccinated patients or patients with past but resolved hepatitis, at Screening
  14. Positive HIV serology results at Screening
  15. Any other reason that in the opinion of the Investigator or the Medical Monitor makes the patient unsuitable for enrollment
  16. Patient is vulnerable (e.g., patient kept in detention)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02808793

Layout table for location information
Charité - Universitätsmedizin Berlin
Berlin, Germany
Sponsors and Collaborators
Allakos, Inc.
Layout table for investigator information
Principal Investigator: Marcus Maurer, MD Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin

Layout table for additonal information
Responsible Party: Allakos, Inc. Identifier: NCT02808793     History of Changes
Other Study ID Numbers: AK002-001
First Posted: June 22, 2016    Key Record Dates
Last Update Posted: March 13, 2019
Last Verified: March 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Keywords provided by Allakos, Inc.:
Indolent Mastocytosis
Additional relevant MeSH terms:
Layout table for MeSH terms
Mastocytosis, Systemic
Neoplasms, Connective Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Skin Diseases
Immune Complex Diseases
Immune System Diseases